Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Recruiting

Phase 2

Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain MetastasesTesting Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases

Sponsor:

SWOG Cancer Research Network

Code:

NCT04647916

Conditions

Anatomic Stage IV Breast Cancer AJCC v8

Invasive Breast Carcinoma

Metastatic HER2 Negative Breast Carcinoma

Metastatic Malignant Neoplasm in the Brain

Prognostic Stage IV Breast Cancer AJCC v8

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

Sacituzumab Govitecan

Study Details

Eligibility Criteria

Study Design

Interventions and Outcome Measures

Central Contacts and Locations

More Information

Trial information was received from ClinicalTrials.gov and was last updated on 2025-03-31. This information was provided to ClinicalTrials.gov by SWOG Cancer Research Network on 2024-08-01.